Entera Bio (ENTX) investor relations material

Introduction and agenda

• Discussion focused on osteoporosis treatment gaps and the opportunity for an oral anabolic therapy, EB613, as a potential first-in-class bone-forming tablet.

• Emphasis on democratizing anabolic therapy by making it accessible and acceptable to a broader patient population.

• Event included perspectives from key opinion leaders in endocrinology and gynecology.

KOL background and credentials

• Dr. Felicia Cosman and Dr. Steve Goldstein are recognized as leading experts in endocrinology and gynecology, respectively, with extensive clinical and research experience in osteoporosis.

Market insights and analysis

• Osteoporosis is primarily managed by gynecologists and primary care, not just specialists, with most patients not reaching specialist care.

• Current treatment is dominated by antiresorptives, with bisphosphonates being the most prescribed globally.

• Injectable anabolics are underutilized due to barriers such as administration route and referral requirements.

• Surveys show 92% of gynecologists would use an oral anabolic if available, compared to only 12% currently using injectables.

• Patient adherence to current oral agents is low due to side effects like acid reflux.